DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06828055

CompletedPhase 2

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Asset

VK2735

Subcutaneous · GLP-1 / GIP dual

Listed sites

15

Recruiting sites

—

Enrollment

280

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06828055
Org study IDVK2735-202

Timeline

Milestones

Study start2024-12-18actual
Study first posted2025-02-14actual
Primary completion2025-06-24actual
Study completion2025-08-15actual
Last update posted2025-10-06actual

Assets

Investigational agents

VK2735

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Age ≥18 years of age at the time of signing the informed consent.

2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI <50 kg/m2

–Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
–BMI calculated at the Screening visit will be used to determine eligibility.

Exclusion criteria

1. History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation

2. Self-reported body weight change of 5% or more within 3 months of screening

3. Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)

4. Current or past diagnosis of chronic pancreatitis

5. Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)

6. Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening

7. Any prescription or over-the-counter medications intended for weight loss within 6 months of screening

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
2
Safety / tolerability / PK
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

Percent (relative) change from baseline in body weight after 13 weeks of treatment

Time frame:13 Weeks

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13. Observed and change from baseline in body weight (kg) after 13 weeks of treatment

Time frame:13 Weeks

threshold achievement, improvement

components≥5% weight-loss responders, ≥10% weight-loss responders

Safety / tolerability / PK

1 endpoint
Other/protocol endpoint

Incidence of Treatment-emergent Adverse Events, incidence of Treatment-Emergent Serious Adverse Events and incidence of Adverse Events of Special Interest

Time frame:13 Weeks

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.